- Home
- NHIC vs ADCT Comparison
NHIC vs ADCT Comparison
Compare NHIC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHIC
- ADCT
- Stock Information
- Founded
- NHIC 2024
- ADCT 2011
- Country
- NHIC United States
- ADCT Switzerland
- Employees
- NHIC N/A
- ADCT N/A
- Industry
- NHIC
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- NHIC
- ADCT Health Care
- Exchange
- NHIC NYSE
- ADCT Nasdaq
- Market Cap
- NHIC 276.7M
- ADCT 241.0M
- IPO Year
- NHIC 2025
- ADCT 2020
- Fundamental
- Price
- NHIC $10.21
- ADCT $2.78
- Analyst Decision
- NHIC
- ADCT Strong Buy
- Analyst Count
- NHIC 0
- ADCT 6
- Target Price
- NHIC N/A
- ADCT $7.80
- AVG Volume (30 Days)
- NHIC 312.0
- ADCT 937.9K
- Earning Date
- NHIC 01-01-0001
- ADCT 08-05-2025
- Dividend Yield
- NHIC N/A
- ADCT N/A
- EPS Growth
- NHIC N/A
- ADCT N/A
- EPS
- NHIC N/A
- ADCT N/A
- Revenue
- NHIC N/A
- ADCT $75,817,000.00
- Revenue This Year
- NHIC N/A
- ADCT $10.65
- Revenue Next Year
- NHIC N/A
- ADCT $15.05
- P/E Ratio
- NHIC N/A
- ADCT N/A
- Revenue Growth
- NHIC N/A
- ADCT 10.49
- 52 Week Low
- NHIC $10.02
- ADCT $1.05
- 52 Week High
- NHIC $10.55
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- NHIC N/A
- ADCT 47.62
- Support Level
- NHIC N/A
- ADCT $3.21
- Resistance Level
- NHIC N/A
- ADCT $3.97
- Average True Range (ATR)
- NHIC 0.00
- ADCT 0.38
- MACD
- NHIC 0.00
- ADCT -0.12
- Stochastic Oscillator
- NHIC 0.00
- ADCT 3.43
About NHIC NEWHOLD INVESTMENT CORP III
NewHold Investment Corp III is a blank check company.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).